Biogen Invites Public to Listen to Webcast of Discussion Regarding FDA Approval of Amevive.Business Editors/Health/Medical Writers CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 31, 2003 Biogen, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BGEN) invites the public to listen to the webcast of the January 31, 2003 discussion regarding the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of Amevive(R) (alefacept). The live webcast begins at 8:30 am (EST EST electroshock therapy. EST abbr. electroshock therapy ) and is accessible through Biogen's homepage, www.Biogen.com. About Biogen Biogen is the world's oldest independent biotechnology company and a leader in biologics research, development and manufacturing. A pioneer in leading edge research in immunology, neurobiology Neurobiology Study of the development and function of the nervous system, with emphasis on how nerve cells generate and control behavior. The major goal of neurobiology is to explain at the molecular level how nerve cells differentiate and develop their and oncology, Biogen brings novel therapies to improve patients' lives around the world through its global marketing capabilities. For press releases and additional information about the company, please visit http://www.biogen.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion